Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Aligos Therapeutics < Previous 1 2 Next > Aligos Therapeutics Appoints David Perry as Vice President of Business Development October 01, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics to Present at Investor Conferences in October September 30, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer September 24, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS HAE NVO PLRX Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH September 19, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024 September 18, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 13, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Announces Reverse Stock Split August 15, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Strengthens Board with Two New Independent Directors August 08, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results August 06, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024 July 30, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. July 22, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB July 10, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 June 05, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 May 22, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH May 21, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results May 07, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 April 30, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study April 25, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD April 25, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 April 09, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects April 03, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies March 27, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects March 18, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results March 12, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 March 05, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 February 26, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024 February 20, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments February 13, 2024 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009) December 07, 2023 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference November 20, 2023 From Aligos Therapeutics Via GlobeNewswire Tickers ALGS < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.